May 2023 in “Elsevier eBooks” Some treatments that modify the immune system might help with certain types of hair loss but haven't been explored for common hair loss alone.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
11 citations
,
July 2017 in “Expert Opinion on Investigational Drugs” New hair loss treatments may include topical medications, injections, and improved transplant methods.
1 citations
,
July 2024 in “Indian Journal of Case Reports” GAPO syndrome causes growth issues, hair loss, missing teeth, and vision problems.
February 2025 in “Journal of the American Academy of Dermatology” People with androgenetic alopecia may have a higher risk of peripheral venous disorders.
1 citations
,
January 2005 in “임상약리학회지” HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
July 2023 in “Cureus” Cetosomal minoxidil alone and with finasteride is effective and well-tolerated for hair loss treatment.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” 5ARI treatment improves hair growth in older men with minimal side effects.
Cadd4 effectively reduces cholesterol levels without side effects.
January 2024 in “The Egyptian Journal of Hospital Medicine” Men with male pattern baldness have higher levels of A-FABP, which might help in early detection.
Eclipta alba L. (Urang-Aring) can help treat hair loss.
April 2024 in “European Journal of Dermatology” The 2940-nm Er: YAG fractional laser may help treat receding frontal hairlines in men with androgenetic alopecia.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
August 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Stem cell therapies show potential for treating hair loss with fewer side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
July 2023 in “Deleted Journal” Alopecia areata is the most common type of baldness treated with corticosteroids and minoxidil.
October 2024 in “Journal of the Endocrine Society” ACTH-dependent Cushing's syndrome linked to metastatic cervical cancer is rare and has high risks.
More men have androgenic alopecia than women, with stress linked to the condition in both genders.
April 2025 in “Journal of Ethnopharmacology” Amygdalin in Persicae Semen may help treat hair loss by promoting hair growth and regulating key pathways.
6 citations
,
February 2019 in “JAAD case reports” Acitretin helped improve hand mobility and skin condition in a patient.
October 2024 in “Journal of the Endocrine Society” Certain genetic variants impair enzyme activity, contributing to non-classic congenital adrenal hyperplasia.
November 2008 in “British Journal of Hospital Medicine” Non-drug methods effectively managed agitation in a patient with a heart device, leading to improved mental function.
January 2000 in “The Journal of Trace Elements in Experimental Medicine” Zinc supplementation effectively treats acrodermatitis enteropathica symptoms.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
3 citations
,
January 2025 in “Scientific Reports” Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
7 citations
,
March 2018 in “Dermatology and therapy” Finasteride is considered the best treatment for hair loss, despite side effects.
June 2024 in “Journal of Education, Health and Sport” Androgenetic alopecia can be treated with minoxidil and finasteride, requiring long-term use and patient cooperation.